Literature DB >> 8335553

Prophylactic effects of recombinant human superoxide dismutase in neonatal lung injury.

J M Davis1, W N Rosenfeld, R J Sanders, A Gonenne.   

Abstract

To determine if recombinant human Cu-Zn superoxide dismutase (rhSOD) would prevent acute lung injury caused by hyperoxia and barotrauma, 26 newborn piglets were studied. Ten piglets were hyperventilated (arterial PCO2 15-20 Torr) with 100% O2 for 48 h. A second group received identical treatment for 4 h (n = 2) or 48 h (n = 8) but was given 5 mg/kg of rhSOD intratracheally at time 0. Six piglets were normally ventilated (arterial PCO2 40-45 Torr) for 48 h with 21% O2. Pulmonary function and tracheal aspirates were examined at time 0 and at 24 and 48 h, and bronchoalveolar lavage was performed at 48 h. In piglets treated with hyperoxia and hyperventilation, lung compliance decreased 42%, and tracheal aspirates showed an increase in neutrophil chemotactic activity (32%), total cell counts (135%), elastase activity (93%), and albumin concentration (339%) over 48 h (P < 0.05). All variables were significantly lower in rhSOD-treated piglets and comparable to normoxic control values. Surfactant remained active in all groups. Immunohistochemistry demonstrated that at 48 h significant rhSOD was distributed homogeneously in terminal airways. Adding rhSOD to tracheal aspirates of hyperoxic hyperventilated piglets did not alter neutrophil chemotaxis, suggesting that rhSOD protected the lung by reducing the production of chemotactic mediators. Results indicate that acute lung injury caused by 48 h of hyperoxia and hyperventilation is significantly ameliorated by prophylactic intratracheal administration of rhSOD.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8335553     DOI: 10.1152/jappl.1993.74.5.2234

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  17 in total

Review 1.  Current perspectives on the drug treatment of neonatal respiratory distress syndrome.

Authors:  D G Sweet; H L Halliday
Journal:  Paediatr Drugs       Date:  1999 Jan-Mar       Impact factor: 3.022

Review 2.  A risk-benefit assessment of drugs used for neonatal chronic lung disease.

Authors:  D G Sweet; H L Halliday
Journal:  Drug Saf       Date:  2000-05       Impact factor: 5.606

Review 3.  Pathogenesis and treatment of bronchopulmonary dysplasia.

Authors:  Jason Gien; John P Kinsella
Journal:  Curr Opin Pediatr       Date:  2011-06       Impact factor: 2.856

Review 4.  The role of genetic polymorphisms in antioxidant enzymes and potential antioxidant therapies in neonatal lung disease.

Authors:  Carlo Dani; Chiara Poggi
Journal:  Antioxid Redox Signal       Date:  2014-02-19       Impact factor: 8.401

5.  Genetic modification of the dilated cardiomyopathy and neonatal lethality phenotype of mice lacking manganese superoxide dismutase.

Authors:  T T Huang; E J Carlson; A M Gillespie; C J Epstein
Journal:  Age (Omaha)       Date:  1998-04

6.  Developmental determinants and changing patterns of respiratory outcomes after preterm birth.

Authors:  Steven H Abman; Simon J Conway
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2014-03

Review 7.  Surfactant therapy for acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; D Willson; R H Notter
Journal:  Crit Care Clin       Date:  2011-07       Impact factor: 3.598

Review 8.  Bronchopulmonary dysplasia: Pathogenesis and treatment.

Authors:  Asfia Banu Pasha; Xiao-Qing Chen; Guo-Ping Zhou
Journal:  Exp Ther Med       Date:  2018-09-19       Impact factor: 2.447

Review 9.  Pharmacotherapy of acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; Gloria S Pryhuber; Patricia R Chess; Bruce A Davidson; Paul R Knight; Robert H Notter
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

10.  Prevention of bronchopulmonary dysplasia.

Authors:  Matthew M Laughon; P Brian Smith; Carl Bose
Journal:  Semin Fetal Neonatal Med       Date:  2009-09-06       Impact factor: 3.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.